Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that NASDAQ has halted trading of the company’s common stock.

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) is meeting today to review NUPLAZID (pimavanserin) for the treatment of patients with psychosis associated with Parkinson’s disease.

The Advisory Committee meeting is scheduled for 8:00 a.m. ET. The briefing materials can be found on the FDA website at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/ucm475314.htm

You May Also Be Interested In

• EU panel backs Acadia's Rett syndrome drug trofinetide for approval
• FDA approves BESREMi Pen for polycythemia vera treatment
• Capricor shares five-year deramiocel data at DMD conference